Avastin Secures Japanese Approval For Colorectal Cancer
This article was originally published in PharmAsia News
Executive Summary
Roche/Genentech's Avastin (bevacizumab) has become the first biologic approved to treat colorectal cancer in Japan; Roche's Japanese partner Chugai announced the approval April 18
You may also be interested in...
Roche Launches Avastin In China For Colon And Rectal Cancer Following Counterfeit Drug Incident In Shanghai
SHANGHAI - Roche announced Sept. 26 the formal launch of its anti-VEGF monoclonal antibody Avastin (bevacizumab) in China for the treatment of metastatic colon and rectal cancer. Roche will also be pursuing other cancer indications in China for the drug
Roche Launches Avastin In China For Colon And Rectal Cancer Following Counterfeit Drug Incident In Shanghai
SHANGHAI - Roche announced Sept. 26 the formal launch of its anti-VEGF monoclonal antibody Avastin (bevacizumab) in China for the treatment of metastatic colon and rectal cancer. Roche will also be pursuing other cancer indications in China for the drug
Erbitux Approval For Colorectal Cancer Sought In Japan
Genentech/Roche’s Avastin, however, could be the first biologic to gain approval for the indication in Japan.